Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
5 papers
Recent·Most cited
C. A. Stewart, L. Diao, Y. Xi, R. Wang, K. Ramkumar, A. G. Serrano, B. L. Rodriguez, B. B. Morris, L. Shen, B. Zhang, Y. Yang, S. H. Hamad, R. J. Cardnell, A. Duarte, M. Sahu, , C. M. Gay
bioRxiv · Dec 19, 2023Cancer Biology
S. Gee, M. Chandiramani, J. Seow, C. Modestini, A. Das, K. J. Doores, R. M. Tribe, D. L. Gibbons
This study examines the impact of maternal SARS-CoV-2 infection on neonatal immunology, finding increased pro-inflammatory cytokines and immune cell percentages in infants exposed in utero.
bioRxiv · May 27, 2021Immunology
A. Sinjab, G. Han, W. Treekitkarnmongkol, K. Kobayashi, P. Brennan, M. Dang, D. Hao, R. Wang, E. Dai, H. Dejima, J. Zhang, E. Bogatenkova, B. Sanchez-Espiridion, K. Chang, D. R. Little, , H. Kadara
This study uses multi-region single-cell sequencing to map the spatial and cellular architecture of early-stage lung adenocarcinoma, revealing geospatial lineage evolution and potential therapeutic targets.
bioRxiv · Sep 4, 2020 · PreprintCancer Biology
D. H. Peng, B. L. Rodriguez, L. Diao, P. O. Gaudreau, A. Padhye, J. K. Ochieng, C. A. Class, J. J. Fradette, L. A. Gibson, L. Chen, J. Wang, L. A. Byers, D. L. Gibbons
This study shows that Th17 cells contribute to resistance to MEK inhibitor and anti-PD-L1 therapy in KRAS/p53 mutant lung cancers and suggests a triple combinatorial therapy to overcome resistance.
bioRxiv · Jun 7, 2020Cancer Biology
C. A. Stewart, C. M. Gay, K. Ramkumar, K. R. Cargill, R. J. Cardnell, M. B. Nilsson, S. Heeke, E. M. Park, S. T. Kundu, L. Diao, Q. Wang, L. Shen, Y. Xi, B. Zhang, C. M. Della Corte, , L. A. Byers
The paper investigates how SARS-CoV-2 infection induces epithelial-mesenchymal transition (EMT) in lung cancer models, leading to changes in gene expression and potential therapeutic targets.
bioRxiv · May 28, 2020 · PreprintCancer Biology